• BCI Home
  • Our research
  • Genitourinary Cancers


Genitourinary Cancers

Why we focus on Genitourinary Cancers

Cancers of the prostate, testis, penis, kidney and bladder account for over 16% of all new cases of cancer and collectively are slightly more common than breast cancer. Prostate cancer is the most common cancer in men and testicular cancer the most common tumour in young men between the ages of 15 and 35 years.

Despite high five year survival rates for testicular (97%) and prostate (80%) cancer, collectively these malignancies account for almost 12% of cancer deaths. Therefore, it remains important to improve our knowledge of the biology of these diseases, and so identify targets for new and novel therapies, particularly for chemoresistance.

What we do

  • Establish and maintain a male urogenital cancer tissue bank.
  • Identify critical genes in testicular tumour cisplatin‑resistance using genome-wide analysis.
  • Identify key biomarkers in penile cancer and investigate the  role of HPV in its development.
  • Focus on resistance mechanisms to targeted therapies used to treat renal cancer.
  • Investigate in vitro and in vivo the therapeutic potential and resistance mechanisms of HER 1-4, FGF-2 and Src-targeted therapy in bladder and renal cancer, and the role of ASS1.
  • Run clinical trials for optimised chemotherapy of testicular tumours.
  • Run translational clinical trials investigating novel targeted and immune therapies.
  • Run clinical trials for new treatments for bladder and renal cancer.

Key Publications

  • Powles et al. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol. 2013 Apr 22.
  • Shamash et al. Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study. Clin Cancer Res 2012; 18:2352-9.
  • Kote-Jarai et al. Seven novel prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43:785-91.
  • Kayani et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 2011; 17: 6021-8.
  • Lorch et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178-84.
  • Welti et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene  2011; 30: 1183-93. 

Who does the research

→ Click here for BCI senior researchers working on genitourinary cancers

Major Funders

  • Orchid
  • Association for International Cancer Research
  • Cancer Research UK
  • GlaxoSmithKline
  • MRC
  • Novartis Pharmaceuticals UK Ltd
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.